Ho­mol­o­gy lays off staff, paus­es rare meta­bol­ic dis­ease tri­al de­spite clin­i­cal hold lift

De­spite get­ting the all-clear from the FDA to restart a clin­i­cal tri­al, a biotech is in­stead paus­ing en­roll­ment and dos­ing to re­fo­cus on an­oth­er can­di­date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER